Table 1

Clinicopathological features and DNA hypomethylation analysis of ovarian cancers and non-neoplastic ovaries

DNA hypomethylation levels have been numbered 0 to 4. Ovarian cancer cases have been ranked with the increase in stage and grade.

AgeaCancerFIGOHistoMGRemTuSat2SatαAll c
33noCYS011
81noOVA0ND1
67noOVA000
62noOVA001
80noOVA0ND1
69noOVA001
31noCYS01ND
72noOVA000
34noOVA011
66noOVA0ND1
74noCYS010
30noOVA001
75noOVA001
62noOVA001
65noOVA011
66noOVA001
38noCYS001
86noOVA011
60noOVA011
61noOVA101
73noOVA001
31noCYS011
26noCYS011
27noCYS111
71noOVA001
59noOVA122
71yesNASERIINA231
75yesIMUCIno011
70yesISERIno122
66yesILMPIno0ND1
72yesILMPIno001
22yesILMPIno011
39yesILMPIno011
50yesILMPIno121
23yesILMPIno112
83yesILMPIno222
56yesIENDIIno12ND
52yesIMUCIIno0ND1
48yesIMUCIIno101
58yesISERIIno011
49yesIMUCIIno011
83yesISERIIno021
72yesIMUCIIno021
44yesIMUCIIno121
63yesIENDIIno012
79yesIMUCIIno112
87yesIMUCIIno112
53yesISERIIno122
51yesIMUCIIno122
36yesIMUCIIno222
48yesIENDIIno222
50yesIMUCIIno311
70yesIMUCIIno322
75yesIENDIIno322
63yesIMUCIIIno121
78yesISERIIIno421
43yesIILMPIno011
83yesIIMUCIIyes111
40yesIIMUCIIyes022
49yesIIENDIIIno222
69yesIISERIIIno321
64yesIISERIIIyes321
81yesIISERIIIno233
44yesIIENDIIIno243
64yesIIIMUCIIno12ND
63yesIIISERIIno011
79yesIIISERIIno011
67yesIIISERIIyes111
66yesIIIMUCIIyes111
51yesIIIENDIIno211
50yesIIISERIIyes211
74yesIIISERIIyes021
68yesIIIMUCIIyes021
74yesIIIMUCIIno121
42yesIIIMUCIIno221
56yesIIIENDIIno221
79yesIIISERIINA221
66yesIIIMUCIIno012
57yesIIIMUCIIyes022
53yesIIISERIIno122
36yesIIIMUCIIno122 .
AgeaCancerFIGOHistoMGRemTuSat2SatαAll c
74yesIIISERIIyes122
65yesIIIMUCIIyes122
78yesIIISERIIyes122
25yesIIIMUCIIyes222
77yesIIISERIIyes320
63yesIIISERIIyes311
59yesIIISERIIyes231
24yesIIISERIIyes232
67yesIIIMUCIIyes232
58yesIIISERIIyes232
58yesIIISERIIno331
42yesIIISERIIyes331
62yesIIIMUCIIno431
69yesIIIMUCIIyes432
61yesIIISERIIyes432
52yesIIISERIIyes342
33yesIIIMUCIIyes442
63yesIIISERIIno233
72yesIIISERIIyes343
73yesIIIMUCIIno443
81yesIIIENDIIno443
49yesIIIENDIIno443
82yesIIIMUCIIyes443
64yesIIISERIIyes443
50yesIIIMUCIIyes444
76yesIIIMUCIIyes011
55yesIIIMUCIIIyes011
72yesIIIMUCIIINA011
77yesIIISERIIIyes121
81yesIIIMUCIIIyes221
48yesIIIMUCIIIyes221
71yesIIISERIIIyes012
55yesIIIMUCIIIyes012
56yesIIIENDIIIyes112
46yesIIISERIIINA122
61yesIIIMUCIIIyes222
57yesIIISERIIIyes222
77yesIIISERIIIyes311
55yesIIIMUCIIIyes131
60yesIIISERIIINA231
67yesIIISERIIIyes232
58yesIIIENDIIIyes432
44yesIIISERIIIyes442
50yesIIISERIIIyes244
73yesIIIENDIIIno443
50yesIIISERIIIyes443
73yesIIISERIIIyes443
71yesIIISERIIIyes444
79yesIIISERIIIyes444
64yesIVENDIIyes1ND1
73yesIVMUCIIyes001
48yesIVSERIIyes101
66yesIVSERIIyes301
76yesIVMUCIIyes343
73yesIVENDIIIyes0NDND
47yesIVSERIIIno011
60yesIVSERIIIyes122
74yesIVSERIIIyes331
57yesIVSERIIIno431
57yesIVENDIIIyes332
  • a Age, age of the corresponding patient in years; Cancer, yes if ovarian cancer and no if non-neoplastic ovary; FIGO, Fédération Internationale des Gynaecologistes et Obstetristes tumor stage I–IV; Histo, histology; CYS, benign cyst of the ovary; OVA, normal ovary; SER, serous cancer; MUC, mucinous cancer; END, endometrioid cancer; LMP, low malignant potential tumor; MG, tumor grade I–III; RemTu, remaining tumor after surgery; ND, not determined because of technical problems with the blot and the availability of only a small amount of DNA; NA, not assessed; Sat2, Satα, All c, DNA hypomethylation levels at Chr1 Sat2, Chr1 Satα, and Satα throughout the centromeres, respectively, on a scale of no hypomethylation (0) to maximum observed hypomethylation (4), as illustrated in Fig. 1 <$REFLINK>